Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors

AIDS Research and Human Retroviruses

Volumn 28, Issue 5, 2012, Pages 478-485

  Espirito Santo, Maria ^a   Santos Costa, Quirina ^a   Calado, Marta ^a   Dorr, Patrick ^b   Azevedo Pereira, J Miguel ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b ABBOTT LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GLYCOPROTEIN; MARAVIROC; MONOCLONAL ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PF 227153; PF 232798; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONCENTRATION (PARAMETERS); HIV TEST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; INFECTION SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; CYCLOHEXANES; GENETIC PREDISPOSITION TO DISEASE; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-2; HUMANS; LIGANDS; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRIAZOLES; VIRUS REPLICATION;

EID: 84860497128     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0124     Document Type: Article

References (58)

1. Clapham PR and McKnight A: Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 2002;83:1809-1829. (Pubitemid 34846445)
2. Kuritzkes DR: HIV-1 entry inhibitors: An overview. Curr Opinion HIV AIDS 2009;4:82-87.
3. Simmons G, Reeves JD, Hibbitts S, et al.: Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev 2000;177:112-126.
4. Zhang YJ, Dragic T, Cao Y, et al.: Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 1998;72:9337-9344. (Pubitemid 28471884)
5. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
6. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV- 1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377. (Pubitemid 26272077)
7. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-4732. (Pubitemid 41552605)
8. DHHS: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aids info.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [1- 139. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 4 Mar 2011 (date last accessed).]
9. Bron R, Klasse PJ, Wilkinson D, et al.: Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J Virol 1997;71:8405-8415. (Pubitemid 27446421)
10. Guillon C, van der Ende ME, Boers PH, Gruters RA, Schutten M, and Osterhaus AD: Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J Virol 1998;72:6260-6263. (Pubitemid 28283428)
11. McKnight A, Dittmar MT, Moniz-Periera J, et al.: A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 1998;72:4065-4071. (Pubitemid 28188711)
12. Azevedo-Pereira JM, Santos-Costa Q, Mansinho K, and Moniz-Pereira J: Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors. Virology 2003;313:136-146. (Pubitemid 37013600)
13. Santos-Costa Q, Mansinho K, Moniz-Pereira J, and Azevedo- Pereira JM: Characterization of HIV-2 chimeric viruses unable to use CCR5 and CXCR4 coreceptors. Virus Res 2009;142:41-50.
14. Reeves JD, Hibbitts S, Simmons G, et al.: Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4- negative cells via CCR5 and CXCR4: Comparison with HIV- 1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999;73:7795-7804. (Pubitemid 29383264)
15. Reeves JD, McKnight A, Potempa S, et al.: CD4-independent infection by HIV-2 (ROD/B): Use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 1997; 231:130-134. (Pubitemid 27238770)
16. CVEDT: Infecção VIH/SIDA-A situação em Portugal, 31 de Dezembro de 2008, Doc. 140; ISSN: 0872-4334. http:// www.aidsportugal.com/recursos/VIH-SIDA-Dezembro-de- 2008.pdf. [1-63. Available at: http://www.aidsportugal.com/ recursos/VIH-SIDA-Dezembro-de-2008.pdf. Accessed 4 Mar 2011 (date last accessed).
17. Dorr P and Perros M: CCR5 inhibitors in HIV-1 therapy. Exp Opinion Drug Discov 2008;3:1345-1361.
18. Khurana S, Kennedy M, King LR, and Golding H: Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. J Virol 2005;79:6791-6800. (Pubitemid 40677311)
19. Lee B, Sharron M, Blanpain C, et al.: Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999;274:9617-9626.
20. Wu L, LaRosa G, Kassam N, et al.: Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997;186:1373-1381. (Pubitemid 27469033)
21. Azevedo-Pereira JM, Santos-Costa Q, Taveira N, Verissimo F, and Moniz-Pereira J: Construction and characterization of CD4-independent infectious recombinant HIV-2 molecular clones. Virus Res 2003;97:159-163. (Pubitemid 37352940)
22. Calado M, Matoso P, Santos-Costa Q, et al.: Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor. Virology 2010;408:174-182.
23. Barre-Sinoussi F, Chermann JC, Rey F, et al.: Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220: 868-871. (Pubitemid 13080157)
24. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, and Popovic M: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986;233:215-219.
25. Broder CC and Jones-Trower A: Coreceptor Use by Primate Lentiviruses. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1999.
26. Baba M, Nishimura O, Kanzaki N, et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96: 5698-5703. (Pubitemid 29234681)
27. Donzella GA, Schols D, Lin SW, et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat Med 1998;4:72-77. (Pubitemid 28133082)
28. Endres MJ, Clapham PR, Marsh M, et al.: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87:745-756. (Pubitemid 26386947)
29. Bleul CC, Farzan M, Choe H, et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-833. (Pubitemid 26299570)
30. Oberlin E, Amara A, Bachelerie F, et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-835. (Pubitemid 26299571)
31. Westby M, Smith-Burchnell C, Mori J, et al.: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81: 2359-2371.
32. Ogert RA, Wojcik L, Buontempo C, et al.: Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008;373:387-399.
33. Pugach P, Ray N, Klasse PJ, et al.: Inefficient entry of vicriviroc- resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 2009;387:296-302.
34. Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, and Clapham PR: Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: Effects of viral diversity, target cell and receptor density. Antiviral Res 2005;68:96-108. (Pubitemid 41565524)
35. Nakata H, Steinberg SM, Koh Y, et al.: Potent synergistic anti-HIV effects using combinations of a CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother 2008;52:2111-2119. (Pubitemid 351758548)
36. Reeves JD, Gallo SA, Ahmad N, et al.: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-16254. (Pubitemid 35462781)
37. Trkola A, Kuhmann SE, Strizki JM, et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400. (Pubitemid 34060372)
38. Brelot A, Heveker N, Pleskoff O, Sol N, and Alizon M: Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol 1997;71:4744-4751. (Pubitemid 27204167)
39. McKnight A, Wilkinson D, Simmons G, et al.: Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997;71:1692-1696. (Pubitemid 27030351)
40. Signoret N, Oldridge J, Pelchen-Matthews A, et al.: Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997;139:651-664. (Pubitemid 27485831)
41. Schols D, Esté JA, Cabrera C, and De Clercq E: T-cellline- tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998;72:4032-4037. (Pubitemid 28188707)
42. Tsibris AM and Kuritzkes DR: Chemokine antagonists as therapeutics: Focus on HIV-1. Annu Rev Med 2007;58: 445-459. (Pubitemid 46706526)
43. Dragic T, Trkola A, Thompson DA, et al.: A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-5644. (Pubitemid 30313771)
44. Seibert C, Ying W, Gavrilov S, et al.: Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006;349:41-54.
45. Kondru R, Zhang J, Ji C, et al.: Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008;73:789-800. (Pubitemid 351397884)
46. Berger EA and Alkhatib G: HIV gp120 interactions with coreceptors: Insights from studies with CCR5-based peptides. Eur J Med Res 2007;12:403-407. (Pubitemid 350011452)
47. Dragic T, Trkola A, Lin SW, et al.: Amino-terminal substitutions in theCCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998;72:279-285. (Pubitemid 28048838)
48. Dragic T: An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 2001;82:1807-1814. (Pubitemid 32717072)
49. Farzan M, Choe H, Vaca L, et al.: A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol 1998;72:1160-1164. (Pubitemid 28116898)
50. Rabut GE, Konner JA, Kajumo F, Moore JP, and Dragic T: Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:3464-3468. (Pubitemid 28175601)
51. Ross TM, Bieniasz PD, and Cullen BR: Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. J Virol 1998;72:1918-1924. (Pubitemid 28100744)
52. Berro R, Sanders RW, Lu M, Klasse PJ, and Moore JP: Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 2009; 5:e1000548.
53. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, and Kuhmann SE: HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361:212-228. (Pubitemid 46551222)
54. Aarons EJ, Beddows S, Willingham T, Wu L, and Koup RA: Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 2001;287:382-390. (Pubitemid 32804023)
55. Jekle A, Chhabra M, Lochner A, et al.: Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies. Antimicrob Agents Chemother 2010;54:734-741.
56. Kuhmann SE, Pugach P, Kunstman KJ, et al.: Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004;78:2790-2807. (Pubitemid 38314338)
57. Blanpain C, Vanderwinden JM, Cihak J, et al.: Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 2002;13:723-737. (Pubitemid 34165096)
58. Armstrong-James D, Stebbing J, Scourfield A, et al.: Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 2010;86:224-226.